What's happening
This bill requires that single source brand-name maintenance medications without a National Average Drug Acquisition Cost be priced at wholesale acquisition cost for Medicaid reimbursement.
Why it matters
Addresses price ambiguity for certain critical medications. By specifying that single source, brand-name maintenance medications without a National Average Drug Acquisition Cost (NADAC) must be reimbursed at wholesale acquisition cost, the bill closes a gap that could otherwise lead to confusion, inconsistent pricing, or delays in Medicaid reimbursements for drugs that often treat chronic conditions.
May impact Medicaid spending and pharmacy reimbursement. Using wholesale acquisition cost as a benchmark can affect how much Medicaid pays pharmacies for these drugs. Depending on how wholesale prices compare to what is currently reimbursed, this could either increase or decrease state expenditures and influence pharmacy willingness to stock and dispense these medications.
Promotes transparency and predictability for providers and patients. By clearly defining the reimbursement mechanism for drugs lacking NADAC pricing, the bill helps pharmacies better anticipate reimbursement rates and ensures patients relying on these maintenance medications are less likely to experience access issues due to reimbursement uncertainties.
Could influence manufacturer pricing strategies. Since wholesale acquisition cost is often set by the drug manufacturer and may not reflect negotiated discounts or rebates, tying Medicaid reimbursement to this figure may affect how manufacturers price single-source, brand-name drugs, potentially prompting future negotiations or policy adjustments.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Set Drug Prices by Cost
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Referred to ways and means
- Reported referred to ways and means
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Set Drug Pricing Standard
In Senate Committee · Health · Sponsor Elijah Reichlin-Melnick
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
6605
2021-2022 Regular Sessions
IN ASSEMBLY
March 19, 2021
Introduced by M. of A. ABINANTI -- read once and referred to the Committee on Health
AN ACT to amend the social services law, in relation to the pricing of single source brand-name maintenance medication for which there is no National Average Drug Acquisition Cost pricing
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Paragraph (b) of subdivision 9 of section 367-a of the social services law, as amended by section 3 of part C of chapter 58 of the laws of 2004, subparagraphs (i) and (ii) as amended by section 7 of part D of chapter 57 of the laws of 2017 and subparagraph (iii) as added by section 29 of part E of chapter 63 of the laws of 2005, is amended to read as follows:
(b) for drugs dispensed by pharmacies:
(i) (A) if the drug dispensed is a generic prescription drug, the lower of: (1) an amount equal to the national average drug acquisition cost set by the federal centers for medicare and medicaid services for the drug, if any, or if such amount if not available, the wholesale acquisition cost of the drug based on the package size dispensed from, as reported by the prescription drug pricing service used by the department, less seventeen and one-half percent thereof; (2) the federal upper limit, if any, established by the federal centers for medicare and medicaid services; (3) the state maximum acquisition cost, if any, established pursuant to paragraph (e) of this subdivision; or (4) the dispensing pharmacy's usual and customary price charged to the general public; (B) if the drug dispensed is available without a prescription as required by section sixty-eight hundred ten of the education law but is reimbursed as an item of medical assistance pursuant to paragraph (a) of subdivision four of section three hundred sixty-five-a of this title, the lower of (1) an amount equal to the national average drug acquisition cost set by the federal centers for medicare and medicaid services
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD09781-01-1
A. 6605 2
for the drug, if any, or if such amount is not available, the wholesale acquisition cost of the drug based on the package size dispensed from, as reported by the prescription drug pricing service used by the department, (2) the federal upper limit, if any, established by the federal centers for medicare and medicaid services; (3) the state maximum acquisition cost if any, established pursuant to paragraph (e) of this subdivision; or (4) the dispensing pharmacy's usual and customary price charged to the general public;
(ii) if the drug dispensed is a brand-name prescription drug, the lower of:
(A) an amount equal to the national average drug acquisition cost set by the federal centers for medicare and medicaid services for the drug, if any, or if such amount is not available, the wholesale acquisition cost of the drug based on the package size dispensed from, as reported by the prescription drug pricing service used by the department, less three and three-tenths percent thereof; or (B) the dispensing pharmacy's usual and customary price charged to the general public; [and]
(iii) notwithstanding subparagraphs (i) and (ii) of this paragraph and paragraphs (d) and (e) of this subdivision, if the drug dispensed is a drug that has been purchased from a manufacturer by a covered entity pursuant to section 340B of the federal public health service act (42 USCA § 256b), the actual amount paid by such covered entity pursuant to such section, plus the reasonable administrative costs, as determined by the commissioner, incurred by the covered entity or by an authorized contract pharmacy in connection with the purchase and dispensing of such drug and the tracking of such transactions. For purposes of this subparagraph, a "covered entity" is an entity that meets the requirements of paragraph four of subsection (a) of such section, that elects to participate in the program established by such section, and that causes claims for payment for drugs covered by this subparagraph to be submitted to the medical assistance program, either directly or through an authorized contract pharmacy. No medical assistance payments may be made to a covered entity or to an authorized contract pharmacy of a covered entity for drugs that are eligible for purchase under the section 340B program and are dispensed on an outpatient basis to patients of the covered entity, other than under the provisions of this subparagraph. Pharmacies submitting claims for reimbursement of drugs purchased pursuant to section 340B of the public health service act shall notify the department that the claim is eligible for purchase under the 340B program, consistent with claiming instructions issued by the department to identify such claims; and
(iv) if the drug is a single source brand-name maintenance medication for which there is no National Average Drug Acquisition Cost pricing, it shall be wholesale acquisition cost.
§ 2. Paragraph (b) of subdivision 9 of section 367-a of the social services law, as added by chapter 170 of the laws of 1994, is amended to read as follows:
(b) for drugs dispensed by pharmacies:
(i) if the drug dispensed is a multiple source prescription drug for which an upper limit has been set by the federal health care financing administration, an amount equal to the specific upper limit set by such federal agency for the multiple source prescription drug[, and];
(ii) if the drug dispensed is a multiple source prescription drug or a brand-name prescription drug for which no specific upper limit has been set by such federal agency, the lower of the estimated acquisition cost of such drug to pharmacies, or the dispensing pharmacy's usual and
A. 6605 3
customary price charged to the general public. Estimated acquisition cost means the average wholesale price of a prescription drug based upon the package size dispensed from, as reported by the prescription drug pricing service used by the department, less ten percent thereof, and updated monthly by the department; and
(iii) if the drug is a single source brand-name maintenance medication for which there is no National Average Drug Acquisition Cost pricing, it shall be wholesale acquisition cost.
§ 3. This act shall take effect on the ninetieth day after it shall have become a law; provided that the amendments to paragraph (b) of subdivision 9 of section 367-a of the social services law made by section one of this act shall be subject to the expiration and reversion of such subdivision pursuant to section 4 of chapter 19 of the laws of 1998, as amended, when upon such date the provisions of section two of this act shall take effect. Effective immediately the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.